Olaparib Improves HRQOL in Prostate Cancer
Researchers assessed pain and HRQOL measures with olaparib vs physician’s choice of treatment in patients with prostate cancer.
Source: cancertherapyadvisor.com
📰 Merck Sharp News
Page 77 - Merck Sharp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Merck Sharp. Real-time updates on events, politics, business and more.
Miller Law LLC and Motley Rice LLC Announce Notice of Certified Litigation Class Action in In re Zetia (Ezetimibe) Antitrust Litigation
Press release content from PR Newswire. The AP news staff was not involved in its creation.
New York United States Health Welfare Fund Optum Health Managed Care Schering Corp Emblem Health Part
Source: apnews.com
Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness — United States, February 2022
This report describes the effectiveness of the influenza vaccine during the 2021-2022 flu season.
Source: cdc.gov
DelveInsight Business Research, LLP: Myelodysplastic Syndrome Market to Climb Swiftly at a 13.2% CAGR During the Study Period [2018-2030], Evaluates DelveInsight
LAS VEGAS, March 8, 2022 /PRNewswire/ -- There has been a mediocre success with the approval of novel agents in Myelodysplastic Syndrome (MDS), where the patients had to wait for more than 13
Source: finanznachrichten.de
NHS watchdog rejects 'seek-and-destroy' breast cancer drug for hundreds of terminal patients
National Institute for Health and Care Excellence (NICE) bosses will not recommend immunotherapy dug pembrolizumab for triple negative breast cancer patients.
United Kingdom United States Delyth Morgan Helen Knight National Institute For Health Cancer Research United Kingdom
Source: dailymail.co.uk
Myelodysplastic Syndrome Market to Climb Swiftly at a 13.2% CAGR During the Study Period [2018-2030], Evaluates DelveInsight
/PRNewswire/ -- There has been a mediocre success with the approval of novel agents in Myelodysplastic Syndrome (MDS), where the patients had to wait for more...
Source: prnewswire.com
Myelodysplastic Syndrome Market to Climb Swiftly at a 13.2% CAGR During the Study Period [2018-2030], Evaluates DelveInsight
/PRNewswire/ -- There has been a mediocre success with the approval of novel agents in Myelodysplastic Syndrome (MDS), where the patients had to wait for more...
Source: prnewswire.com
China on the Move: Lesson from China's National Negotiation of Drug Prices in 2021 | Insights
In December 2021, China’s National Healthcare Security Administration (NHSA) published the 2021 National Reimbursement Drug List (2021 NRDL), implementing greater pricing discounts than those seen in 2020.
Hunan Province United States Junshi Toripalimab Adcs Trastuzumab Emtansine Novartis Zolgensma Beigene Tislelizumab
Source: gtlaw.com
Deputy premier: Sarawak govt plans to secure supplies of Pfizer's Covid-19 drug Paxlovid | Malaysia
KUCHING, March 6 — The Sarawak government has made plans to secure supplies of Pfizer’s Covid-19 drug Paxlovid, says Deputy Premier Datuk Seri Dr Sim Kui Hian. According to him, the Sarawak Covid-19 Advisory Group (Scovag) led by its chairman Datuk Dr Andrew Kiyu, has been in talks with Pfizer...
Source: malaymail.com
Genome and Company announces Clinical Trial Collaboration with MSD to evaluate 'GEN-001' in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients
/PRNewswire/ -- Genome and Company (KOSDAQ: 314130, CEO∙CTO: Jisoo Pae∙Hansoo Park), a leading global microbiome anti-cancer drug development company,...
Source: prnewswire.com